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Abstract
Background:  HIV-1 is characterized by its rapid genetic evolution and high diversity as a
consequence of its error-prone reverse transcriptase and genetic recombination. This latter
mechanism is responsible for the creation of circulating recombinant forms (CRFs) found in nature.
Previous studies from our lab group have shown that the epidemic in Argentina is characterized by
one highly prevalent circulating recombinant form, CRF12_BF, and many related BF recombinant
forms. Since transcriptional transactivation of the HIV-1 long terminal repeat (LTR) promoter
element requires the essential viral Tat protein, since these genetic structures underwent
recombination in variants widely spread in South America, the aim of this work was to study
transcriptional activity associated with the recombinant LTR and Tat elements.
Results:  Differential transcriptional activity was measured for the BF recombinant LTR/Tat
complex that is present in widely spread viral variants was demonstrated. This analysis
demonstrated a higher activity for the BF complex when compared to its B subtype counterpart.
Conclusion: This study indicates structural and functional consequences of recombination events
within the LTR promoter and Tat transactivator protein of a naturally occurring HIV-1
recombinant form.
Background
Human immunodeficiency virus type 1 (HIV-1) is a dip-
loid retrovirus whose genome consists of two RNA mole-
cules per virion. This viral RNA serves as the template for
proviral DNA synthesis by the virus-encoded reverse tran-
scriptase (RT) enzyme.
HIV-1 is characterized by its rapid genetic evolution and
high diversity, as demonstrated by the large number of
different HIV-1 strains isolated around the world. This
rapid genetic variation provides the virus with maximum
adaptation efficiency and presents serious challenges for
chemotherapy and vaccine development against HIV-1
infection.
Major mechanisms that contribute to HIV-1 genetic varia-
tion include: a high mutation rate as a consequence of its
error-prone reverse transcriptase, and recombination
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[1,2]. Genetic recombination plays an important role in
the evolution of HIV-1 [3]. Since two RNA molecules are
packaged into each virion, RT can use portions of each
RNA as template during reverse transcription to generate
a recombinant viral DNA, redistributing the genetic infor-
mation. Therefore, rapid recombination of the HIV-1
genome creates a vast advantage for viral evolution and an
enormous difficulty for the host to control the infection.
Accumulating evidence has confirmed the existence of
recombinant HIV-1 in nature [4]. Some of these recom-
binant viruses have become fixed in the human popula-
tion and are referred to as circulating recombinant forms
(CRFs), and in a few cases CRFs have become the predom-
inant strain in specific geographic areas [5,6].
Previous studies from our lab group have shown that the
epidemic in Argentina is characterized by a circulating
recombinant form, CRF12_BF, and many related BF
recombinant forms [7-9]. The analysis also showed that
HIV-1 BF recombinant viruses have diverse mosaic struc-
tures that are phylogenetically related in their F and
selected B fragments to the F1 subtype and with BF recom-
binant viruses from Brazil, respectively [9,10].
After HIV-1 gains entry to its target cell, the virus integrates
into its host genome. Once integrated, the provirus serves
as a template for transcription of viral genes. Regulation of
early events in viral transcription is mediated by direct
interaction between cellular transcription factors and cis-
acting elements located in the HIV promoter or LTR (Long
Tat variants from BF recombinant forms obtained from 23 Argentinean patients Figure 1
Tat variants from BF recombinant forms obtained from 23 Argentinean patients. Samples are named either as ID/
accession number (when they were firstly described by our group) or GenBank accession number only. A. Four distinguishable 
genetic patterns (named Tat1, Tat2, Tat3 and Tat4) were recognized by boostcaning analysis. Samples showing each recombi-
nation pattern are indicated on the right. B. Tat primary structure from Argentinean samples. Several amino acid substitutions 
are observed when compared to the B subtype prototype sequences. Substitutions are found in every functional domain being 
the core and basic domains the most conserved.Retrovirology 2006, 3:14 http://www.retrovirology.com/content/3/1/14
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Terminal Repeat) region. At this early phase, the HIV-1
promoter is under control of local chromatin environ-
ment, which determines the basal transcriptional activity
(reviewed in [11]). As the viral Tat protein accumulates in
the nucleus, it dramatically increases transcriptional rate
by modifying chromatin conformation at the integration
site, adjusting the activity (initiation and elongation) of
RNA polymerase II and promoting NF-κB activation [12-
15]. Other mechanisms of Tat-mediated activation of viral
transcription have been described [14,16-18].
As both viral elements mainly involved in HIV-1 tran-
scriptional transactivation (Tat protein and the LTR pro-
moter) underwent intersubtype genomic recombination
in variants widely spread in South America, the following
questions can be addressed: What are the implications of
intersubtype recombination on both the Tat protein and
LTR promoter sequences and their activities? How may
these modifications in transcriptional properties influ-
ence viral infectivity? The aim of this work was to reveal
possible transcriptional variation due to the LTR and Tat
recombinant structures. In this study we report not only
structural but also functional consequences of recombina-
tion events in the LTR promoter and transactivation pro-
tein of the BF recombinant form.
(The research performed by Gabriela Turk was in partial
fulfilment of her Ph.D. degree, School of Medicine, Uni-
versity of Buenos Aires, Buenos Aires, Argentina).
Results
Structural analysis of Tat protein and LTR promoter from 
BF samples
Primary structure of tat variants from HIV-1 BF intersubtype 
recombinant forms
As it has been reported, BF recombinant forms show dif-
ferent mosaic patterns at the pol region [10]. When analyz-
ing the tat coding region of previously reported full length
sequences corresponding to BF intersubtype recombinant
forms, 4 different structures, named Tat1, Tat2, Tat3 and
Tat4, were found (Figure 1A). Tat1, the most prevalent
variant, was observed in CRF12_BF prototypic strains
(ARMA159, ARMA185, URTR23 and URTR35) and in
other 14 sequences. In these samples, the tat  coding
region is predominantly F subtype with a B segment in the
second half of the first exon. Tat2 and Tat3 are each repre-
sented by only 2 sequences (ARCH014, AF408632 and
ARMA070, AF408628, respectively). In samples showing
the second Tat variant, each exon clustered with a different
subtype. Tat3 shares the same BF recombinant exon 1
with Tat1, whereas exon 2 is pure B subtype. Tat4 was only
found in ARMA062 and it clustered entirely with the B
subtype, showing no recombination breakpoints.
As regards the polymorphisms observed in our samples,
we firstly focused on target residues for post-translational
modifications (See Figure 1B for primary sequence
details). Tat undergoes multiple post-translational modi-
fications, such as acetylation, ubiquitination and methyl-
ation, which are responsible for the regulation of its
interaction either with RNA and/or cellular factors such as
cyclinT1, p300/CBP and PCAF [19]. Our analysis revealed
that most of these target sites are conserved among BF
viral variants circulating in our country. For instance, K28,
K50 and K51 have been widely described as targets for
PCAF and p300 acetyltransferases and they are crucial for
transcriptional activation. These residues are highly con-
served in all the sequences analyzed here, pointing out the
importance of these residues for optimal Tat activity. K71,
a residue whose ubiquitination results in a non-proteo-
lytic mechanism controlling Tat activity [20], is also
highly conserved among all our samples but 3
(ARMA036, AF408628 and AY037280), which showed
substitutions to either arginine (R) or glutamic acid (E).
Finally, Tat is also substrate for arginine methylation at its
basic domain. This domain spans residues 49 to 57, it is
composed of 6 Rs and includes K50 and K51. Residues at
positions 49 and 55 are conserved in all the analyzed sam-
ples meanwhile R52, R53, R56 and R57 are conserved in
all but 1, 2, 1 and 5 samples, respectively. It is worth not-
ing that all these substitutions are shown in different sam-
ples, i.e. none of the samples have more than one
simultaneous R substitution at the R rich motif. Another
interesting feature is that the most polymorphic residue at
the basic domain is R57 which is the most distant residue
from K50. It may be hypothesized that residues closer to
K50 are important for Tat biological activity while the oth-
ers are more dispensable.
Another noteworthy polymorphism was found at K29.
Substitutions in this position were present in 19 out of 23
analyzed samples, mostly to R or glutamine (Q). Eleven
out of 19 samples showed a simultaneous change at posi-
tion 24 (N to K) while the remaining 8 showed an N to R
change.
As regards Tat domains, the N-terminal or acidic domain
is predicted to form an α-helix [21]. In addition to the
negatively charged amino acids placed in this domain, B
subtype Tat has 2 positively charged residues (R7 and
K12) that are likely to stabilize the secondary structure.
Twenty out of 23 BF samples showed asparagine (N) sub-
stitutions in one (n = 2) or both (n = 18) residues. As N
has no charge at physiological pH, these substitutions
change the net charge of the whole domain. When analyz-
ing the core and basic domains, no major changes were
observed.Retrovirology 2006, 3:14 http://www.retrovirology.com/content/3/1/14
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Phylogenetic analysis of 24 LTR sequences from Argentinean samples Figure 2
Phylogenetic analysis of 24 LTR sequences from Argentinean samples. A neighbour-joining phylogenetic tree was 
built and maximum parsimony bootstrap values were calculated. The genetic distance corresponding to the length of the 
branches is shown by the bottom line. Reference samples are those recommended by the Los Alamos Database. ▲  and ● : 
Unknown samples.Retrovirology 2006, 3:14 http://www.retrovirology.com/content/3/1/14
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The C-terminal domain (aa 73–101), encoded by the sec-
ond exon of the gene, shows a considerable variability
among different viral strains and only a few biological
activities have been attributed to it. The first functional
motif identified in this domain was the RGD motif which
is involved in integrin-mediated cell adhesion [22]. Only
7 of the samples examined here-in preserved this motif
intact where most of them showed mutations to RGN. It
was also observed that motif ESKKKVESKA is strikingly
conserved among Argentinean sequences, although the
functional significance of such motif has not been exam-
ined in detail yet. This amino acid sequence is present in
the F subtype Tat but is not present in the B clade Tat.
LTR sequences from BF recombinant variants
DNA samples previously characterized as BF intersubtype
recombinant forms at the vpu  locus (F02 to F121),
obtained from newly infected individuals between 2003
and 2004, were used as template for LTR amplification
(HXB2 nt -327 to 179). Direct sequencing was performed
on the PCR products, and subtyping was performed by
aligning with reference sequences from different subtypes.
The population-based phylogenetic analysis showed that
11 out of 24 samples clustered together with B subtype
references, and the remaining 13 clustered with F subtype
references, confirming its BF recombinant nature (Figure
2). Distance scanning and bootscanning analysis were
performed for all samples. This analysis further confirmed
the information given by the phylogenetic tree, even for
samples ARCH003, F2, F34, F55, F72 and F108 that
seemed to be less phylogenetically related to their corre-
sponding clusters (data not shown).
To investigate the presence of transcription factor bind-
ings sites (TFBS) in these recombinant LTRs, sequences
were analyzed using the TFSEARCH program (available at
http://www.cbrc.jp/research/db/TFSEARCH.html). Major
TFBS were included in this analysis, i.e. USF, TATA box,
RBEIII, SP1, AP1 and NFκB (Figure 3). Sample ARMA 159,
prototype of the CRF12_BF, showed an additional TATAA
box located at position -136. Also sample F121 turned out
to have the additional TATAA sequence. It is remarkable
that both sequences, F121 and ARMA 159, clustered
closely in the phylogenetic tree (see figure 2). This addi-
tional TATAA sequence has also been reported for subtype
E LTR and it has been shown as functionally inactive in
this subtype [23]. van Opijnen et al have also shown that
a CATAA box is the actual regulatory sequence at the LTR
promoter, and it was present in all the samples analyzed
here [23].
RBEIII is a cis-acting element known to be binding site for
RBF-2, the Ras response element binding factor 2, recently
described as the USF1/USF2 heterodimer [24]. This site
was found in duplicate in only 1 of the 24 samples studied
(F14). Even though this duplication has been described
previously [25,26] and it is one of the most frequently
occurring polymorphism of the HIV-1 LTR, its clinical
implications are still not clear. Estable et al suggested that
this polymorphism would be selected in vivo because it
LTR maps for transcription binding sites Figure 3
LTR maps for transcription binding sites. Organizations of HIV-1 subtype B, F and CRF12_BF recombinant LTRs are 
shown. Subtype B has been used as a reference for protein binding sites.Retrovirology 2006, 3:14 http://www.retrovirology.com/content/3/1/14
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could down-regulate the HIV-1 transcription during
monocyte to macrophage differentiation or T-cell activa-
tion [25]. On the other hand, no significant differences
were found in number and structure of USF, SP1, AP1,
and NFκB sequences.
The TAR RNA element is positioned immediately after the
transcription start site (nt +1 to +59) while forming a sta-
ble hairpin structure, and having a wide natural variation
that has been described previously [27]. This element was
analyzed and changes in relevant nucleotide positions in
the loop region were found (Figure 4). Nucleotides in this
loop have been shown to be essential in the Tat-CyclinT1/
CDK9 interaction for activating transcription elongation
from HIV-1 LTR. Changes in this region (nucleotides 30–
35) have been related to variations in the interaction with
CyclinT1 while changes at positions 23–24 (bulge region)
have been shown to affect the interaction with Tat [28].
Four of the analyzed samples (F27, F55, F67 and F92) pre-
sented changes in the highly conserved 6-nucleotides
sequence (CUGGGA) and changes located at positions
23–24 that form another loop in the TAR stem. Changes
were found at positions 31 (U31), 32 (G32) and 33
(G33). Nucleotide positions 32 and 34 in the loop region
are essential for CycT1-Tat interactions with TAR RNA.
The identity of nucleotides U31 and G33 is not critical,
but they contribute to the stabilization of the RNA-protein
complex.
Functional analysis of of Tat protein and LTR promoter 
from BF samples
GFP transactivation in GHOST cells
With the purpose of evaluating both protein expression
and activity of our full length tat-coding constructs,
GHOST cells were transiently transfected with
pTATBF(ARMA159) and pTATB(NL4-3). Forty-eight hours post-
transfection tat mRNA was detected by using a qualitative
RT-PCR (Figure 5A). As regards Tat biological activity, it
was invariably found (after four independent assays, each
one in triplicate) that there is no significant difference
between TatB(NL4-3) and TatBF(ARMA159) to transactivate the
expression of an HIV-2 LTR-driven reporter gene (Figure
5B).
Tat capability to restore viral transactivation in HLM1 cells
In order to evaluate if Tat derived from a pure HIV-1 sub-
type or a prototypic recombinant form share the same
ability to transactivate viral production, HLM1 cells were
either pTATBF(ARMA159)  or pTATB(NL4-3)  transfected. Viral
production was evaluated at several time points after
transfection in cell culture supernatants. Qualitative RT-
PCR showed that tat mRNA was readily detected as early
as 6 hs post transfection (Figure 6A). However, viral pro-
duction was not evident until 12 hs post-transfection (not
shown). Up to 36 hs post-transfection, TatB(NL4-3) – and
TatBF(ARMA159) – driven viral transactivation reached simi-
lar levels (Figure 6B). However, at this time point, it was
consistently seen that TatB(NL4-3) tended to show higher
transactivation levels (although non-significant). In
agreement with this observation, 48 hs post-transfection it
was observed that TatB(NL4-3)  showed a significantly
improved capacity to drive viral production (p = 0.004).
Transcriptional levels of BF recombinant LTRs
Previous study has shown that LTRs from different sub-
types have slightly different transcriptional capacities
[29,30]. By co-transfecting 293T cells with plasmids con-
taining either the LTRB(NL4-3) or LTRBF(ARMA159), and plas-
mids pTatB(NL4-3) or pTatBF(ARMA159) their transcriptional
activities were tested and compared. FACS analysis, per-
formed 48 hs after transfections, showed an increased
transcriptional level associated to the BF recombinant LTR
when compared to the subtype B LTR (p = 0.02). This dif-
ference was evident when pLTRBF(ARMA159) plasmid was co-
transfected with pTatBF(ARMA159)  (LTRBF(ARMA159)  /
TatBF(ARMA159) vs. LTRB(NL4-3)/TatB(NL4-3) and LTRBF(ARMA159)
/TatB(NL4-3) vs. LTRBF(ARMA159) /TatBF(ARMA159)). Slightly but
not significant differences in transcriptional levels were
observed when LTRs were co-transfected with a Tat of dif-
ferent subtype (LTRBF(ARMA159) /TatB(NL4-3) vs. LTRB(NL4-3)/
TatBF(ARMA159)) (Figure 7).
TAR structure of BF recombinant variants Figure 4
TAR structure of BF recombinant variants. TAR sec-
ondary structure of CRF12_BF (ARMA159), and BF recom-
binant isolates F27, F55 and F92 are shown. B (NL4-3) and F 
(isolate 93BR020) subtype TARs were used as reference. 
Nucleotide changes are highlighted. Changes were found at 
positions 31 (U31), 32 (G32) and 33 (G33) in these isolates. 
Nucleotide position 32 is one of the essentials for CycT1-Tat 
interactions with TAR RNA. Nucleotides U31 and G33 are 
not critical, but they contribute to the stabilization of the 
RNA-protein complex.Retrovirology 2006, 3:14 http://www.retrovirology.com/content/3/1/14
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ARCH003 and ARCH005 are samples obtained from ver-
tically infected children whose genetic structure suggested
the circulation of the BF recombinant forms since the
mid-1980's [31]. ARCH003 has a B subtype LTR and a BF
recombinant structure in the tat  coding region while
ARCH005 has a BF-like LTR and Tat structures. When LTR
transcriptional activity from ARCH003 sample was ana-
lyzed it turned out to be higher when it was transactivated
by the B subtype Tat protein than when its own BF Tat pro-
tein (pTatARCH003) was used (p = 0.001). ARCH005 LTR
was only evaluated using the B subtype Tat and it did not
show significant differences when compared to the
LTRB(NL4-3)/TatB(NL4-3)  complex. Unfortunately, the tat
region from this sample could not be amplified.
Discussion
This study characterizes the genetic structure of LTRs
sequences and Tat proteins from BF recombinant variants
and, also, analyzes the transcriptional activity associated
with these recombinant variants.
LTR diversity among different HIV-1 subtypes may affect
the binding of both cellular and viral transcription factors,
thus influencing the transcription level. This effect, in
turn, may have biological consequence for the different
HIV-1 clades. Although studies on LTR transcriptional
activity of different HIV-1 subtypes have been previously
performed [23,29,30], the consequences of intersubtype
recombination on HIV-1 transcriptional activity has not
been analyzed in much detail. Moreover, most studies
that involved the analysis of LTRs from different subtypes
always used the B subtype Tat protein as transactivator,
which hampers the proper evaluation of the results in
terms of transcriptional advantages, due to sequence
changes in Tat protein activity due to recombination
events. In this in vitro study, a differential transcriptional
activity associated to the BF recombinant LTR/Tat com-
plex found in widely spread viral variants in Argentina was
shown. This analysis demonstrated a higher activity for
the LTRBF(ARMA159)  /TatBF(ARMA159)  complex when com-
pared to its B subtype counterpart. It also showed that LTR
and Tat proteins from different subtypes (B vs. BF) ren-
dered a lower activity when Tat and LTR did not match in
their subtype, i.e. LTRB(NL4-3)/TatBF(ARMA159)  and
LTRBF(ARMA159) /TatB(NL4-3). Phylogenetic analysis of LTR
sequences from the prototypic CRF12_BF sample
(ARMA159) demonstrated that it clustered together with
F reference sequences. The improved transcriptional levels
measured for BF recombinant LTRs are consistent with
previously reported high activity of the F subtype LTR
[29].
Several substitutions were found in the tat gene and in the
LTR sequence from BF samples when compared to their B
subtype counterparts, which may account for the
improved transcriptional potential observed here. When
the Tat sequence was analyzed in detail, it was found that
previously reported elements considered to be crucial for
Tat activity were conserved among BF viral variants thus
stressing the key role of K28, K50, K51 and the basic and
core domains in transactivation. These 2 regions are par-
ticularly important for Tat function as they are involved in
cyclin T1 binding, nuclear localization, Tat-mediated pro-
apoptotic-effects and interaction with a wide subset of
transcriptional coactivators and modifying enzymes [16-
18]. More recently, it was found that Tat is also able to
abrogate RNA silencing by inhibiting the ability of DICER
to process precursor double-stranded RNAs into siRNAs.
Authors demonstrate that K51 is a key residue for Tat sup-
pressor of RNA silencing activity [32].
Previous publications describing HIV-1 gene expression
driven by clade-specific Tat proteins found that Tat pro-
Transactivation of GFP expression in GHOST cells Figure 5
Transactivation of GFP expression in GHOST cells. 
A) tat mRNA was detected in pTat transfected cells, but not 
in untransfected cells or cells transfected with empty vector, 
by RT-PCR (right panel). Amplification of actin mRNA was 
also evaluated as an internal control (left panel). B) Tat 
expressing vectors were capable to transactivate the expres-
sion of the gfp gene placed downstream the LTR from HIV-2. 
No statistical difference was found between TatB(NL4-3) and 
TATBF(ARMA159). UT: Untransfected cells, NC: Negative con-
trol, MeanI: Mean Fluorescence Intensity, Te: Transfection 
efficiency. Data presented here is representative of 4 inde-
pendent assays.
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teins from E and C subtypes are the most active in trans-
activation [33,34]. Higher transactivation potential of
subtype E Tat was attributed to its longer half-life, which
in turn, was postulated to be dependent on its ubiquitina-
tion pattern [33]. Since the E subtype Tat protein contains
more lysine residues acting as ubiquitin acceptor, ubiqui-
tination could occur more readily and contribute to its
extended half-life. Most BF Tat variants (14 out of 23),
including CRF12_BF prototypic strains have a lysine at
position 24 instead of the asparagine residues that charac-
terize B subtype isolates. K24 is a shared feature with the
E subtype Tat and, although speculative, this may partially
account for the higher activity observed for Tat BF.
In order to assess the transactivating capacity of TatB(NL4-3)
vs. TatBF(ARMA159)  proteins we used GHOST cells as a
reporter system and also HLM1 cells to observe restora-
tion of viral production. In GHOST cells, we were not able
to observe differences between TatB(NL4-3)  and
TatBF(ARMA159). As reporter gene expression in these cells is
driven by the LTR promoter from HIV-2, it is possible that
both proteins, although structurally distinct, share the
same mechanism to modulate transcription in this sys-
tem. In HLM1 cells, TatB(NL4-3) showed an improved abil-
ity to rescue viral production from the Tat-defective
provirus (which harbours a B-matched LTR). This is con-
sistent with the results obtained from the co-transfection
assays where the LTRB(NL4-3)/TatBF(ARMA159) combination
had the lowest transcriptional potential. A naturally
occurring LTRB(NL4-3)/TatBF(ARMA159)  combination was
observed in sample named ARCH003. Transmission of
this viral variant can be tracked back to the year 1986. It
was isolated from a vertically infected child with no evi-
dence of reinfection. In vitro co-transfection assays
showed that the LTRARCH003/TatARCH003 complex had sig-
nificantly lower transactivation potential when compared
to other LTR/Tat combinations but when LTRARCH003 was
co-transfected with Tat B, higher expression of the reporter
gene was obtained. According to the extensive molecular
epidemiology data in our region, we suggest that early BF
recombinant forms had a recombination breakpoint at
the Vpu/Tat region but conserved the LTR of B subtype.
This would render the emerging variants less competent
for transcriptional activation, and natural selection would
have forced the gaining of an F-like LTR. In other words, it
is possible to speculate that F subtype sequences present
in the BF recombinant would be advantageous for the
virus since these changes would increase its fitness, in
terms of transcription. Nevertheless it is not clear yet if
this advantage correlates with what is observed in the field
of the epidemiology.
The LTR analysis showed moderate diversity between the
sequences analyzed. An extra TATA box was found in
CRF12_BF sample and in other patient isolate (F121).
Although this extra sequence is postulated to be inactive
in other HIV subtype, i.e. E subtype, in vitro studies on this
issue are currently in progress. Nucleotide changes were
also found in the TAR region. This region is important for
the Tat/TAR/cellular factor interactions implicated in the
activation of transcription. Base changes at positions 31,
32 and 33 of the loop may affect the interaction with pro-
teins Cyclin T1 and CDK9. Major TFBS appeared to be
conserved between samples with the exception of RBEIII,
which was found in duplicate in one sample. This factor is
important for transcriptional silencing in resting infected
cells and this is the most common polymorphism in clin-
ical isolates. These changes could be, at least in part,
related to the differential transcriptional activities
observed in the BF recombinant variants.
Conclusion
In summary, data presented here shows transcriptional
differences linked to the LTR and tat coding region of BF
recombinants circulating in Argentina. Transcriptional
improvement may be a consequence of the recombina-
tion process between 2 different HIV-1 subtypes and selec-
Restoration of viral production in HLM1 cells Figure 6
Restoration of viral production in HLM1 cells. A) tat 
mRNA was detected in pTAT transfected cells as early as 6 
hours post-transfection (right panels). Amplification of actin 
mRNA was used as an internal control (left panels). B) 
Kinetic of p24 production after cell transfection with Tat 
encoding vectors. UT: Untransfected cells, NC: Negative 
control, Hs pt: Hours post-transfection. Data presented here 
is representative of 3 independent assays.
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tion forces favouring the spreading of these recombinant
forms. The fitness of BF primary isolates is currently being
evaluated in our laboratory. Preliminary results indicate a
certain replicative advantage of BF over B isolates, in dual
infection-competition assays (Rubio AE et al, manuscript
in preparation). The correlation between these in vitro
data and the patients' clinical outcome is still not clear
due to the lack of follow-up studies in BF infected
patients. Studies on viral load set-point, disease progres-
sion as well as transmissibility of BF variants will be help-
ful to estimate the impact of emerging recombinant HIV-
1 genotypes on the spreading epidemic.
Methods
DNA samples and amplification
Extensive HIV-1 genotyping studies have been conducted
by our group. Genomic DNA from HIV-1 infected patients
involved in these studies was used to amplify the LTR
region and tat full coding sequence. Samples previously
characterized as BF intersubtype recombinant forms at the
vpu  locus (F02 to F121) were obtained from newly
infected individuals between 2003 and 2004. ARMA159 is
the prototypic strain for CRF12_BF (GenBank accession
N° AF385936; [9]), ARCH003 and ARCH005 (GenBank
accession N° AY037267 and N° AF454487, respectively)
were obtained from children born to HIV-1 infected
mothers. Full length and partial sequences of ARCH003
and ARCH005 samples are available, respectively. Both
samples show recombination between B and F subtypes
although ARCH005 seems to be closely related to
CRF12_BF [31]. HIV-1 molecular clone pNL4-3 was used
as B subtype template. LTR region (HXB2 nt -327 to 179)
and first and second Tat exons were amplified by nested
PCR. All reactions were conducted using the proof-read-
ing Vent DNA polymerase (New England Biolabs, USA).
Primers are listed in Table 1. Pasting of tat exons was per-
formed in one further PCR round using primers TECORI
and TXHOI. This allowed us to place both exons together
in frame in one final amplicon.
Cloning and sequencing
Constructs named pLTRB(NL4-3), pLTRBF(ARMA159),
pLTRARCH003 and pLTRARCH005 were generated by cloning
the LTR amplicons into the pGLOW reporter vector (Inv-
itrogen, USA), upstream of the GFP reporter gene. Full
length tat  amplicons were cloned into the commercial
expression vector pTARGET (Promega, USA) generating
pTATB(NL4-3), pTATBF(ARMA159)  and pTATARCH003. Colony
screening was performed by colony-PCR and restriction
analysis. Minipreps of positive clones were obtained
(QIAprep Miniprep kit, QIAgen INC, USA) and
sequenced using the Big Dye Terminator sequencing kit
(Amersham, Sweden) on an automatic sequencer
(Applied Biosystems DNA sequencer 3100). Nucleotide
sequences were analyzed and manually adjusted using
Sequencher 4.0.5 software (Gene Codes Co, USA).
Selected constructs were large-scale prepared using the
HighSpeed Midiprep kit (QIAgen INC) and quantified in
agarose gels.
Cells and DNA transfection assays
HLM1, GHOST and 293T cell lines were used in this
study. HML1 cells are HeLaT4+ cells stably transduced
with a tat-defective HIV-1 molecular clone and were
obtained through the AIDS Research and Reference Rea-
gent Program, Division of AIDS, NIAID, NIH: HLM30
cells from Dr Reza Sadaie [35]. HLM1 cells are negative for
virus particle production but they can be induced to
Transactivation of B and BF LTRs by clade B and BF specific  Tat proteins (A: CRF12_BF; B: ARCH003 and ARCH005) Figure 7
Transactivation of B and BF LTRs by clade B and BF 
specific Tat proteins (A: CRF12_BF; B: ARCH003 and 
ARCH005). 293T cells were transfected with GFP reporter 
constructs containing HIV-1 clade-specific LTRs in absence 
or presence of expression plasmids encoding Tat B(NL4-3) or 
TatBF(ARMA159). Relative transactivation is expressed as mean 
fluorescence obtained by FACS analysis. Cells transfected 
only with LTRs constructs were used as negative controls. 
Error bars indicate standard errors. 
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express high levels of non-infectious HIV-1 and syncytial
cells after transfection or coculture with tat-expressing
clones. GHOST is a human osteosarcoma (HOS) derived
cell line stably transduced with MV7neo-T4 retroviral vec-
tor and stably co-transfected with the HIV-2 LTR driving
GFP construct (Kewalramani VN, unpublished data).
293T is a highly transfectable kidney-derived epithelial
cell line.
Cells were grown at 37°C and 5% CO2 in a humidified
incubator. 293T cells were cultured in Dulbecco's modi-
fied Eagle's medium (DMEM, Gibco BRL, USA) supple-
mented with 10% fetal bovine serum (FBS, Gibco BRL), 2
mM L-glutamine (Gibco BRL), 100 U/ml penicillin
(Gibco BRL) and 100 mg/ml streptomycin (Gibco BRL).
GHOST cells were grown in the same medium plus 400
µg/ml geneticin (Gibco BRL). HML1 cells were cultured in
DMEM supplemented with 10 µg/ml gentamicin (Gibco,
BRL) and 10% FBS.
HLM1, GHOST and 293T cells transient transfections
were carried out using Lipofectamine2000 (Invitrogen),
following manufacturer instructions. For single transfec-
tions experiments confluent cells grown in 60 mm Petri
dishes were transfected with 8 µg of the corresponding
pTAT construct. For 293T co-transfections, 5 µg of pLTR
and 0.5 µg of pTAT were used. Untransfected cells as well
as cells transfected with empty vectors were always used as
negative controls. Also, empty vectors were used to keep
DNA amount constant in dual transfection experiments.
RT-PCR
Total cellular RNA was extracted from 107 cells using Tri-
zol reagent (Gibco BRL). Three µg of RNA were reverse
transcribed using MMLV reverse transcriptase (Invitrogen)
and an oligo-dT primer. The mix was supplemented with
RNAse inhibitors (Invitrogen) in a final volume of 20 µl.
Two µl of cDNA were used for tat PCR amplification using
TECOI and TXHOI primers. Amplification of β-actin was
used as RNA quality control. Actin PCR was also per-
formed on 2 µl of the RT reaction using primers β1 and
β2-actin (Table 1).
GFP transactivation in GHOST cells
The use of the green fluorescent protein (GFP) gene as a
reporter molecule has been widely used to study the tran-
scriptional activity of the HIV LTRs from different isolates.
The fluorescence intensity of GFP is a direct measurement
of the transcriptional activity of the promoter that directs
the expression of the protein. Upon infection or transfec-
tion of cultured cells with a Tat coding plasmid, GFP
expression can be measured using a fluorescence activated
cell sorter. One of the main advantages in using this sys-
tem is that it is possible to simultaneously measure trans-
fection efficiency and fluorescence intensity of the
transfected live cells without the need of co-transfection of
a reference plasmid [36,37].
Tat constructs were used for single transfections of
GHOST cells. Expression of the reporter gene was ana-
lyzed by flow cytometry (FACS Coulter Epics XL, Becton
Dickinson, USA) in cells harvested 48 hs post-transfec-
tion. Living cells were gated by forward angle and side-
scatter light. A minimum of 10,000 events were collected
for each histogram. Analytical gates were set such that 1%
or fewer of negative control cells fell within the positive
regions. Data analysis was carried out using System II soft-
ware (Beckman Coulter INC, USA). Four independent
assays were conducted, each in triplicate. Data was
expressed as the Mean Fluorescence Intensity (MeanI)/%
of GFP positive cells ratio.
Restoration of transactivation in HLM1 cells
Tat constructs were used for single transfections of HLM1
cells. Cell culture supernatants were collected 6, 12, 24, 36
and 48 hs post-transfection in order to evaluate viral pro-
duction. p24 titers were subsequently determined
through a commercial ELISA assay (Murex, Abbott, USA)
including a calibration curve. Three independent assays
were conducted, each in triplicate.
Subtype-specific LTR transactivation assays
293T were double transfected with different pLTR and
pTat constructs. Expression of the reporter gene driven by
the interaction between Tat and the corresponding LTR
sequence was analyzed by flow cytometry as described
above.
Statistical analysis
All data was expressed as mean ± SD unless, otherwise
stated. Significance (p  < 0.05) between means of two
experimental groups was evaluated using the Student's t
test for independent samples (through the Primer of
Biostatistics version 4.02 software).
Phylogenetic and TFBS analysis
A multiple alignment of the newly generated LTR
sequences with selected reference sequences was per-
formed using ClustalX, and visually corrected with the
BioEdit version 5.0.9 http://www.mbio.ncsu.edu/bioedit/
bioedit.html. Subtype ascribing of LTR sequences was per-
formed by constructing phylogenetic trees by Neighbor-
joining using the Kimura 2-parameter model with the
MEGA v.3.0 program http://megasoftware.net. Bootstrap
analysis was done to assess the stability of the nodes.
Recombinant analysis was performed by bootscanning by
using the SimPlot v.2.5 program http://
www.welch.jhu.edu and visual inspection of alignments
were used in order to identify breakpoints in recombinant
sequences. After identification of the breakpoints, sub-Retrovirology 2006, 3:14 http://www.retrovirology.com/content/3/1/14
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regions of the alignment were re-analyzed by neighbor-
joining with bootstrapping to confirm the subtype assign-
ment. Reference sequences included in the analysis were
those recommended by the Los Alamos HIV sequence
database http://hiv-web.lanl.gov.
LTR sequences were also analyzed in search of transcrip-
tion factors binding sites (TFBS) using a web-based
method (TFSEARCH Data Base, http://www.cbrc.jp/
research/db/TFSEARCH.html).
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
GT and MC contributed equally to this work designing
and performing the experiments and during the manu-
script preparation. AM provided help with LTR amplifica-
tion and cloning. AER participated during the
experimental design and provided technical help. MGC
helped with phylogenetic analysis and data interpreta-
tion. HS supervised experimental design and writing of
the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
We thank Dario Dilernia for providing DNA samples from BF infected 
patients as well as Mariel Bibini and Monica Saracco for their excellent tech-
nical assistance on flow cytometry.
Gabriela Turk and Mauricio Carobene were supported by the Argentinean 
National Research Council (CONICET) and Fogarty International Center/
NIH grant through the AIDS International Training and Research Program 
at Mount Sinai School of Medicine-Argentina Program (Grant # 5D43 
TW0010137), respectively. This research has been also partially funded by 
the Argentinean Agency for the Promotion of Science and Technology 
(ANPCYT, Grant N° 14104).
We would also like to thank Mr. Sergio Mazzini for assistance during the 
preparation of the manuscript for publication.
References
1. Jones JS, Allan RW, Temin HM: One retroviral RNA is sufficient
for synthesis of viral DNA.  J Virol 1994, 68(1):207-216.
2. Mansky LM, Temin HM: Lower in vivo mutation rate of human
immunodeficiency virus type 1 than that predicted from the
fidelity of purified reverse transcriptase.  J Virol 1995,
69(8):5087-5094.
3. Robertson DL, Sharp PM, McCutchan FE, Hahn BH: Recombination
in HIV-1.  Nature 1995, 374(6518):124-126.
4. Robertson DLGFHBHSM: Intersubtype recombinant HIV-1
sequences.  In Human retroviruses and AIDS: a compilation and analysis
of nucleic acid and amino acid sequences Edited by: Korber BHBFB-
MJWLLMGMCFKC. Los Alamos, NM , Los Alamos National Labora-
tory; 1997:III-25 - III-30. 
5. Gao F, Robertson DL, Morrison SG, Hui H, Craig S, Decker J, Fultz
PN, Girard M, Shaw GM, Hahn BH, Sharp PM: The heterosexual
human immunodeficiency virus type 1 epidemic in Thailand
is caused by an intersubtype (A/E) recombinant of African
origin.  J Virol 1996, 70(10):7013-7029.
6. Renjifo B, Chaplin B, Mwakagile D, Shah P, Vannberg F, Msamanga G,
Hunter D, Fawzi W, Essex M: Epidemic expansion of HIV type 1
subtype C and recombinant genotypes in Tanzania.  AIDS Res
Hum Retroviruses 1998, 14(7):635-638.
7. Avila MM, Pando MA, Carrion G, Peralta LM, Salomon H, Carrillo
MG, Sanchez J, Maulen S, Hierholzer J, Marinello M, Negrete M, Rus-
sell KL, Carr JK: Two HIV-1 epidemics in Argentina: different
genetic subtypes associated with different risk groups.  J
Acquir Immune Defic Syndr 2002, 29(4):422-426.
8. Carobene MG, Rubio AE, Carrillo MG, Maligne GE, Kijak GH, Quarl-
eri JF, Salomon H: Differences in frequencies of drug resist-
ance-associated mutations in the HIV-1 pol gene of B
subtype and BF intersubtype recombinant samples.  J Acquir
Immune Defic Syndr 2004, 35(2):207-209.
9. Carr JK, Avila M, Gomez Carrillo M, Salomon H, Hierholzer J, Watan-
aveeradej V, Pando MA, Negrete M, Russell KL, Sanchez J, Birx DL,
Andrade R, Vinoles J, McCutchan FE: Diverse BF recombinants
have spread widely since the introduction of HIV-1 into
South America.  Aids 2001, 15(15):F41-7.
10. Quarleri JF, Rubio A, Carobene M, Turk G, Vignoles M, Harrigan RP,
Montaner JS, Salomon H, Gomez-Carrillo M: HIV type 1 BF
recombinant strains exhibit different pol gene mosaic pat-
terns: descriptive analysis from 284 patients under treat-
ment failure.  AIDS Res Hum Retroviruses 2004, 20(10):1100-1107.
11. Wu Y: HIV-1 gene expression: lessons from provirus and non-
integrated DNA.  Retrovirology 2004, 1(1):13.
12. Barboric M, Peterlin BM: A new paradigm in eukaryotic biology:
HIV Tat and the control of transcriptional elongation.  PLoS
Biol 2005, 3(2):e76.
13. Brady J, Kashanchi F: Tat gets the "green" light on transcription
initiation.  Retrovirology 2005, 2:69.
14. Li L, Li HS, Pauza CD, Bukrinsky M, Zhao RY: Roles of HIV-1 aux-
iliary proteins in viral pathogenesis and host-pathogen inter-
actions.  Cell Res 2005, 15(11-12):923-934.
15. Raha T, Cheng SW, Green MR: HIV-1 Tat stimulates transcrip-
tion complex assembly through recruitment of TBP in the
absence of TAFs.  PLoS Biol 2005, 3(2):e44.
16. Brigati C, Giacca M, Noonan DM, Albini A: HIV Tat, its TARgets
and the control of viral gene expression.  FEMS Microbiol Lett
2003, 220(1):57-65.
17. Huigen MC, Kamp W, Nottet HS: Multiple effects of HIV-1 trans-
activator protein on the pathogenesis of HIV-1 infection.  Eur
J Clin Invest 2004, 34(1):57-66.
18. Marcello A, Lusic M, Pegoraro G, Pellegrini V, Beltram F, Giacca M:
Nuclear organization and the control of HIV-1 transcription.
Gene 2004, 326:1-11.
19. Hetzer C, Dormeyer W, Schnolzer M, Ott M: Decoding Tat: the
biology of HIV Tat posttranslational modifications.  Microbes
Infect 2005, 7(13):1364-1369.
20. Bres V, Kiernan RE, Linares LK, Chable-Bessia C, Plechakova O, Tre-
and C, Emiliani S, Peloponese JM, Jeang KT, Coux O, Scheffner M,
Benkirane M: A non-proteolytic role for ubiquitin in Tat-medi-
Table 1: List of primers used for PCR amplification
Target region Primer name (sequence 5'-3')
LTR 1R F: LTR1 (cacacaaggctayttcctga)
R: JL17 (cattctgcagcttcctcattgat)
2R F: LTR3 (tggatggtgctwcaagytagt)
R: LTRrev (tgctagagattttccacactgac)
tat 1st exon 1R F: polseq2 (cgggtttattacagggacagc)
R: ES33 (cattgccactgtcttctgctc)
2R F: TECORI (cagaataggaattctgcgacagagaag) *1
R: TE1 (gggatatgggttgctttgatagagaagc)
tat 2nd exon 1R F: KS2mod (ttctatagtggatagagttaggaaggg)
R: OFM19mod (gcactcaaggcaagctttattgaggc)
2R F: TE2 (gcttctctatcaaagcaacccatatccc)
R: TXHOI (acaggctcctcgaggtcgtccc) *2
β-actin F: β1 (ggacctgactgactacctcatgaa)
R: β2 (gatccacatctgctggaaggtgg)
1R = 1st round, 2R = 2nd round. Introduced EcoRI (*1) and XhoI (*2) 
restriction sites are underlined. F: Forward. R: Reverse.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Retrovirology 2006, 3:14 http://www.retrovirology.com/content/3/1/14
Page 12 of 12
(page number not for citation purposes)
ated transactivation of the HIV-1 promoter.  Nat Cell Biol 2003,
5(8):754-761.
21. Kuppuswamy M, Subramanian T, Srinivasan A, Chinnadurai G: Multi-
ple functional domains of Tat, the trans-activator of HIV-1,
defined by mutational analysis.  Nucleic Acids Res 1989,
17(9):3551-3561.
22. Brake DA, Debouck C, Biesecker G: Identification of an Arg-Gly-
Asp (RGD) cell adhesion site in human immunodeficiency
virus type 1 transactivation protein, tat.  J Cell Biol 1990,
111(3):1275-1281.
23. van Opijnen T, Kamoschinski J, Jeeninga RE, Berkhout B: The human
immunodeficiency virus type 1 promoter contains a CATA
box instead of a TATA box for optimal transcription and
replication.  J Virol 2004, 78(13):6883-6890.
24. Chen J, Malcolm T, Estable MC, Roeder RG, Sadowski I: TFII-I reg-
ulates induction of chromosomally integrated human immu-
nodeficiency virus type 1 long terminal repeat in
cooperation with USF.  J Virol 2005, 79(7):4396-4406.
25. Estable MC, Bell B, Hirst M, Sadowski I: Naturally occurring
human immunodeficiency virus type 1 long terminal repeats
have a frequently observed duplication that binds RBF-2 and
represses transcription.  J Virol 1998, 72(8):6465-6474.
26. Koken SE, van Wamel JL, Goudsmit J, Berkhout B, Geelen JL: Natu-
ral variants of the HIV-1 long terminal repeat: analysis of
promoters with duplicated DNA regulatory motifs.  Virology
1992, 191(2):968-972.
27. Berkhout B: Structural features in TAR RNA of human and
simian immunodeficiency viruses: a phylogenetic analysis.
Nucleic Acids Res 1992, 20(1):27-31.
28. Lund LH, Wahren B, Garcia-Blanco MA: A functional genetic
approach suggests a novel interaction between the human
immunodeficiency virus type 1 (HIV-1) Tat protein and HIV-
1 TAR RNA in vivo.  J Gen Virol 2003, 84(Pt 3):603-606.
29. Jeeninga RE, Hoogenkamp M, Armand-Ugon M, de Baar M, Verhoef
K, Berkhout B: Functional differences between the long termi-
nal repeat transcriptional promoters of human immunodefi-
ciency virus type 1 subtypes A through G.  J Virol 2000,
74(8):3740-3751.
30. van Opijnen T, Jeeninga RE, Boerlijst MC, Pollakis GP, Zetterberg V,
Salminen M, Berkhout B: Human immunodeficiency virus type 1
subtypes have a distinct long terminal repeat that deter-
mines the replication rate in a host-cell-specific manner.  J
Virol 2004, 78(7):3675-3683.
31. Gomez Carrillo M, Avila M, Hierholzer J, Pando M, Martinez PL,
McCutchan FE, Carr JK: Mother-to-child HIV type 1 transmis-
sion in Argentina: BF recombinants have predominated in
infected children since the mid-1980s.  AIDS Res Hum Retrovi-
ruses 2002, 18(7):477-483.
32. Bennasser Y, Le SY, Benkirane M, Jeang KT: Evidence that HIV-1
encodes an siRNA and a suppressor of RNA silencing.  Immu-
nity 2005, 22(5):607-619.
33. Desfosses Y, Solis M, Sun Q, Grandvaux N, Van Lint C, Burny A,
Gatignol A, Wainberg MA, Lin R, Hiscott J: Regulation of human
immunodeficiency virus type 1 gene expression by clade-spe-
cific Tat proteins.  J Virol 2005, 79(14):9180-9191.
34. Kurosu T, Mukai T, Komoto S, Ibrahim MS, Li YG, Kobayashi T, Tsuji
S, Ikuta K: Human immunodeficiency virus type 1 subtype C
exhibits higher transactivation activity of Tat than subtypes
B and E.  Microbiol Immunol 2002, 46(11):787-799.
35. Sadaie MR, Tschachler E, Valerie K, Rosenberg M, Felber BK, Pavlakis
GN, Klotman ME, Wong-Staal F: Activation of tat-defective
human immunodeficiency virus by ultraviolet light.  New Biol
1990, 2(5):479-486.
36. Daelemans D, De Clercq E, Vandamme AM: A quantitative GFP-
based bioassay for the detection of HIV-1 Tat transactivation
inhibitors.  J Virol Methods 2001, 96(2):183-188.
37. Kar-Roy A, Dong W, Michael N, Li Y: Green fluorescence protein
as a transcriptional reporter for the long terminal repeats of
the human immunodeficiency virus type 1.  J Virol Methods
2000, 84(2):127-138.